Navigation Links
Solos Endoscopy Finishes the 3rd Quarter With a Net Profit

BOSTON, Nov. 22, 2011 /PRNewswire/ -- Solos Endoscopy, Inc.'s (OTCPK: SNDY) is pleased to announce that it finished the 3rd Quarter with a Net Profit of $73,895.  Solos Endoscopy has consummated agreements which resulted in the Forgiveness of debt of $299,082 for the Three Months period ending September 30, 2011.  The signed settlement agreement and new consulting agreement result in a reduction of ongoing expenses by approximately $40,000 per quarter.

Solos Endoscopy posted its financial statements for period ended September 30, 2011.  While the Company saw a modest decrease in sales over the three month period, the Net Profit is a result of Management's cost cutting and debt reduction efforts.  Management is extremely pleased with the increase in demand for its new MammoView® instrument line.

The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

"Solos management has worked extremely hard to position the Company for future success.  This is represented by our tireless efforts to work with our creditors, while remaining focused on future product development. We have allocated significant resources to the development of the MammoView® instrument line.  The fact that we have taken this tremendous product from concept phase to sales in dozens of hospitals across the Country is truly amazing.  I'd like to thank the shareholders for all their continued support," stated Bob Segersten, President of Solos Endoscopy, Inc.

Please visit for more information.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at:

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact: Amanda Segersten,

SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
2. Solos Endoscopy Goes Google
3. Solos Endoscopy Finishes the 3rd Quarter Strong
4. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
5. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
6. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
7. Solos Endoscopy to Reduce Debt by Over $620,000
8. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
9. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
10. Solos Endoscopy, Inc. To Launch New Corporate Website
11. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
Post Your Comments:
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
Breaking Medicine News(10 mins):